Novel therapies in vasculitis

Bibliography

• ZEEK PM: Periarteritis nodosa and other forms of necrotising angiitis. N Engl. j Med. (1953) 248:764.
   PubMed Web of Science ®Google Scholar
• FAUCI AS, HAYNES BF, KATZ P: The spectrum of vasculitis: Clinical, pathologic, immunologic and therapeutic considerations. Ann. Intern. Med. (1978) 89:660.
   PubMed Web of Science ®Google Scholar
• JENNETTE JC, FALK RJ, ANDRASSY K et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. (1994) 37:187.
   PubMed Web of Science ®Google Scholar
• SOMER T, FINEGOLD SM: Vasculitides associated with infections, immunization, and antimicrobial drugs. an. Infect. Dis. (1995) 20:1010–1036.
   Web of Science ®Google Scholar
• VALENTE RIVI, CONN DL: Current therapies for systemic vasculitis. Semi]. Neural (1994) 14(4):380–386.
   PubMed Web of Science ®Google Scholar
• FINKEL TH, TOROK TJ, FERGUSON PJ et al: Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet (1994) 343:1255–1258.
   PubMed Web of Science ®Google Scholar
• MADER R, NARENDRAN A, LEWTAS J et al: Systemic vasculitis following influenza vaccination: Report of 3 cases and literature review. j Rheumatal (1993) 20:1429–1431.
   PubMed Web of Science ®Google Scholar
• NUYTS GD, VAN VLEM E, DE VOS A et al.: Wegener granulomatosis is associated to exposure to silicon compounds: A case-control study. Nephrol. Dial. Transplant. (1995) 10:1162–1165.
   Google Scholar
• GREGORINI G, FERIOLI A, DONATO F et al: Association between silica exposure and necrotizing crescentic glomerulonephritis with p-ANCA and anti-MPO antibodies: A hospital-based case-control study. Adv. Exp. Med. Biol. (1993) 336:435–440.
   PubMedGoogle Scholar
• STEGEMAN CA, TERVAERT JW, SLUITER WJ, MANSON WL, DEJONG PE, KALLENBERG CG: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granuomatosis. Ann. Intern. Med. (1994) 120:12–17.
   PubMed Web of Science ®Google Scholar
• PINCHING AJ, REES AJ, PUSSELL BA, LOCKWOOD CM, MITCHISON RS, PETERS DK: Relapses in Wegener's Granulomatosis: the role of infection. BMJ (1980) 281:836–838.
   PubMed Web of Science ®Google Scholar
• GORDON LK, GOLDMAN M, HOFFMAN GS etal.: Giant Cell Arteritis- Characterization of Candidate Microbial Sequences and evidence of immunologic relevance. (Abstract 1928 in 2000 ASM of American College of Rheumatology). Arthritis Rheum. (2000) 43(9):(Suppl.).
   Google Scholar
• ROTTEM M, COTCH MF, FAUCI AS, HOFFMAN GS: Familial vasculitis: report of 2 families. j Rheumatal. (1994) 21:561–563.
   PubMed Web of Science ®Google Scholar
• HUANG D, GISCOMBE R, ZHOU Y, LEFVERT AK: Polymorphisms in CTLA-4 but not tumor necrosis factor-a or interleukin-113 genes are associated with Wegener's Granulomatosis. j Rheumatal (2000) 27:2
   Google Scholar
• CUPPS TR: Therapeutic use. In: BoumpasDT moderator. Clucocarticaid therapy for immune mediated diseases: basic and clinical correlates. Ann. Intern. Med. (1993) 119:1198–1208.
   Google Scholar
• WILKE WS, HOFFMAN GS: Treatment of corticosteroid-resistant giant cell arteritis. Rheum. Dis. Glin. N Am. Feb (1995) 21:159–171
   Google Scholar
• HUNDER GG, SHEPS SG, ALLEN GL, JOYCE JW: Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: Comparison in a prospective study. Ann. Intern. Med. (1975) 82:613.
   PubMed Web of Science ®Google Scholar
• JOVER JA, HERNANDEZ-GARCIA C, MORADO IM et al: Combined treatment of giant-cell-arteritis with methotrexate and prednsone. Ann. Intern. Med. (2001) 134:106–114.
   PubMed Web of Science ®Google Scholar
• FLEMING RA: An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy (1997) 17:146S.
   PubMed Web of Science ®Google Scholar
• FAUCI AS, WOLFF SM: Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) (1973) 52:535–561.
   PubMed Web of Science ®Google Scholar
• FAUCI AS, HAYNES BF et al: Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann. Intern Med. (1983) 98:76–85.
   PubMed Web of Science ®Google Scholar
• HOFFMAN GS, KERR GS, LEAVITT RY et al: Wegener's Granulomatosis: an analysis of 158 patients. Ann. Intern. Med. (1992):488–498.
   PubMed Web of Science ®Google Scholar
• HOFFMAN GS: Treatment of Wegener's Granulomatosis: time to change the standard of care? Arthritis Rheum. (1997) 40(12):2099–2104.
   Google Scholar
• WESTMAN KW, BYGREN PG, OLSSON H, RANSTAM J, WIESLANDER J: Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. j Am. Soc. Nephrol (1998) 9(5):842–852.
   PubMed Web of Science ®Google Scholar
• GUILLEVIN L, CORDIER J-F, LHOTE F et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalised Wegener's granulomatosis. Arthritis Rheum. (1997) 40:2187–2198.
   PubMed Web of Science ®Google Scholar
• ADU D. PALL A. LUQMANI RA. et al: Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM(1997) 90(6):401–409.
   PubMed Web of Science ®Google Scholar
• FRASIER LH, KANEKAI S, KEHRER JP: Cyclophosphamide toxicity: characterising and avoiding the problem. Drugs (1991) 42:781–795.
   PubMed Web of Science ®Google Scholar
• GODEAU B, MAINARDI JL, ROUDOT-THRAVAL F, PIETTE JC: Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann. Rheum. Dis. (1995) 54:991–994.
   PubMed Web of Science ®Google Scholar
• OGNIBENE FP, SHELHAMER JH, HOFFMAN GS et al.: Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am. j Respir: Grit. Care Med. (1995) 151:795–799.
   PubMed Web of Science ®Google Scholar
• FISHMAN JA: Prevention of infection due to pneumocystis carinii. Aritimicrob. Agents Chemother. 42(5):995–1004.
   Google Scholar
• GOREN MP: Oral Mesna: A review Semi]. Orical (1992) 19:65.
   PubMedGoogle Scholar
• LYNCH JP, III, MCCUNE WJ: Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders: state of the art. Am. I Resp. Grit. Care Med. (1997) 155:395–420.
   PubMed Web of Science ®Google Scholar
• BRANTEN AJ, REICHERT LJ, KOENE RA, WETZELS JF: Oral cyclophosphamide versus chlorambucil in the treatment of patients with membraneous nephropathy and renal insufficiency. QJM(1998) 5:359–366.
   Google Scholar
• ISRAEL H, PATCHEVSKY AS: Treatmentof Wegener's granulomatosis of the lung. Am. Med. (1975) 58:671–673.
   PubMedGoogle Scholar
• CANON GW, JACKSON CG, SAMUELSON COJ et al: Chlorambucil therapy in rheumatoid arthritis: Clinical experience in 28 patients and literature review. Semi]. Arthritis Rheum. (1985) 15:106.azathioprine. Drug Metab. Rev (1985) orr)rrcrxi rc DTC'T'DT TD r`.16: 157.
   Google Scholar
• PEDERSEN ES, 13I0TRUP C: Etoposide: more effective and less bone-marrow toxic than standard immunosuppressive therapy in systemic vasculitis? Nephrol Dial. Tramplant (1996) 11:1121–1123.
   Web of Science ®Google Scholar
• CRUZ DD, PAYNE H, TIMOTHY A, HUGHES GRV: 'Response of cyclophosphamide -resistant Wegener's granulomatosis to etoposide. Lancet (1992) 340:425–426.
   PubMed Web of Science ®Google Scholar
• RHEUMATIC DISEASE CLINICS OF NORTH AMERICA: Methotrexate (1997) 3(4):Nov.
   Google Scholar
• HOFFMAN GS, LEVITT RY, KERR GS, FAUCI AS: The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum. (1992) 35:1322–1328.
   PubMed Web of Science ®Google Scholar
• LANGFORD CA, FAUCI AS, TALAR-WILLIAMS C et al: Treatment of Wegener's granulomatosis with methotrexate and glucocorticoids: update on rate of relapse. Arthritis Rheum. (1996) 39(Suppl):211.
   Google Scholar
• DEGROOT K, REINHOLD-KELLER E, TATSIS E et al.: Therapy for the maintenance of remission in sixty-five patients with generalised Wegener's granulomatosis. Arthritis Rheum. (1996) 39:2052–2061.
   PubMed Web of Science ®Google Scholar
• HOFFMAN GS, LEAVITT RY, KERR GS et al. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum. (1994) 37:578–582.
   PubMed Web of Science ®Google Scholar
• STACK PS: Methotrexate for Urticarial vasculitis. Ann. Allergy (1994) 2:36–38.
   Google Scholar
• WILLIAMS HC, PEMBROKE AC: Methotrexate in the treatment of vasculitic cutaneous ulceration in rheumatoid arthritis. j. Royal Soc. Med. (1989) 82(12):763.
   PubMed Web of Science ®Google Scholar
• GHATE JV, JORIZZO JL: Behcet's disease and complex aphthosis.j. Am. Acad. Dermatol (1999) 40:1–8.
   PubMed Web of Science ®Google Scholar
• SIMONART T, DUREZ P, MARGAUX J, VAN GEERTRUYDEN J, GOLDSCHMIDT D: Parent D. Cutaneous necrotizing vasculitis after low dose methotrexate therapy for rheumatoid arthritis: a possible manifestation of methotrexate hypersensitivity. Clin. Rheumatol. (1997) 16(6):623–625.
   Google Scholar
• VAN SK, JOHNSON CA, PORTER WR: The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and
   Google Scholar
• BRAND WEIN, S, ESDAILLE J, DANHOFF D, TANNENBAUM H: Wegener's granulomatosis. Clinical features and outcome in 13 patients. Arch. Intern. Med. (1983) 143:476–479.
   Google Scholar
• RANSOM JT: Mechanism of action of mycophenolate mofetil. Ther. Drug Monitoring (1995) 17:681.
   PubMed Web of Science ®Google Scholar
• WAISER J, BUDDE K, BRAASCH E, NEUMAYER HH: Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil. Am. j. Kid Dis. (1999) 34(3):e9.
   PubMedGoogle Scholar
• NOWACK R, GOBEL U, KLOOKER P et al.: Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement.j Am. Soc. Nephrol (1999) 10(9):1965–1971.
   Google Scholar
• STEFFAN HO, NEIL CLIPSTONE, LUIKA TIMMERMANN, CRABTREE R et al: The mechanism of action of Cyclosporin A and FK506. Cliii. Immunol Immunopathol (1996) 80(3):540–545 Article:0140.
   Google Scholar
• FATHMAN CG, MYERS BD: Cyclosporin therapy for autoimmune disease. N Eng. j Med. (1992) 326:1693–1694.
   PubMed Web of Science ®Google Scholar
• HAUBITZ M, KOCH KM, BRUNKHORST R: Cyclosporin for the prevention of disease reactivation in ANCA-associated vasculitis. Nephrol Dial. Transplant. (1998) 13(8):2074–2076.
   PubMed Web of Science ®Google Scholar
• GEORGANAS C, LOAKIMIDIS D, KONTOMERKOS T et al.: Relapsing Granulomatosis: successful treatment with cyclosporin-A. Cliii. Rheumatol. (1996) 15(2):189–192.
   PubMed Web of Science ®Google Scholar
• MASUDA K, NAKAJIMA A, URAYAMA A et al.: Double masked trial of cyclosporin versus colchicine and long term open study of cyclosporin in Behcet's Disease. Lancet (1989) 1:1093–1096.
   PubMed Web of Science ®Google Scholar
• The efficacy of cyclosporin A in the treatment of Behcet's disease. Ophthalmic Surgery (1994) 25(5):321–327.
   PubMedGoogle Scholar
• COVELLI M, LAPADULA G, PIPITONE V: Cogan's syndrome: unsuccessful outcome with early combination therapy. Clin. & Exp. Rheum. (1999) 17(4):479–483.
   PubMed Web of Science ®Google Scholar
• KOGA T, YANO T, MOCHIZUKI M et al.: Pulmonary infiltrates recovered by FK 506 in a patient with Behcet's disease. Chest (1993) 104(1):309–311.
   PubMed Web of Science ®Google Scholar
• SLOPER CM, POWELL RJ: Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporin. Ophthalmology (1999) 106(4):723–728.
   PubMed Web of Science ®Google Scholar
• MOCHIZUKI M, IKEDA E, SHIRAO M et al.: Preclinical and clinical study of FK506 in uveitis. Cum: Eye Res. (1992) 11(Suppl.):87–95.
   Google Scholar
• ROAT MI, THOFT RA, THOMSON AW, STARZL TE: Treatment of Cogan's syndrome with FK506: a case report. TramplantaL Proc. (1991) 23(6):3347.
   PubMed Web of Science ®Google Scholar
• LENARDO, T, CALABRESE LH: The Role of thalidomide in the treatment of rheumatic disease. j. Clin. Rheum. (2000) 6:1.
   Google Scholar
• POWELL RJ, GARDNER-MEDWIN JM: Guideline for the clinical use and dispensing of thalidomide. Postgrad. Med. 1 (1994) 70:901-904.
   Google Scholar
• HAMURYUDAN V, MAT C, SAIP S et al: Thalidomide in the treatment of the mucocutaneous lesions of Behcet's syndrome: a randomized, double-blind, placebo controlled trial. Ann. Intern. Med. (1998) 128:443–459.
   PubMed Web of Science ®Google Scholar
• GARDNER-MED WINJM, SMITH NJ, POWELL RJ: Clinical experience with thalidomide in the management of severe oral and genital ulcerations in conditions such as Behcet's disease: use of neurophysiologic studies to detect thalidomide neuropathy. Ann. Rheum. Dis. (1994) 53:828–832.
   PubMed Web of Science ®Google Scholar
• JORIZZO JL, SCHMALSTIEG FC, SOLOMON AR JR et al: Thalidomide effects in Behcet's syndrome and pustular vasculitis. Arch. Int. Med. (1986) 146(5):878–881.
   PubMed Web of Science ®Google Scholar
• SULLIVAN TE KING LE, BOYD AS: Colchicine in dermatology. I Am. Acad. Dermatol (1998) 39:993–999.
   PubMed Web of Science ®Google Scholar
• HAZEN PG, MICHEL B: Management of necrotising vasculitis with colchicine: improvement inpatients with cutaneous lesions and Behcet's syndrome. Arch. Dermatol. (1979) 115:1303–1306.
   PubMed Web of Science ®Google Scholar
• SANDER HM, RANDLE HW: Use of colchicine in Behcet's syndrome. Culls (1986) 37:344–348.
   Google Scholar
• AKTULGA E, ALTAC M, MUFTUOGLU A et al.: A double blind study of colchicine in Behcet's disease. Haematologica (1980) 65:399–402.
   PubMed Web of Science ®Google Scholar
• CALLEN JP: Colchicine is effective in controlling chronic leukocytoclastic vasculitis. j. Am. Acad. Dermatol (1985) 13(2Pt):193–200.
   Google Scholar
• MURAMATSU C: Urticarial vasculitis: response to dapsone and colchicine. I Am. Acad. Dermatol. (1985) 13:1055.
   PubMed Web of Science ®Google Scholar
• ASHERSON RA, BUCHANAN N, KEN WRIGHT S, FLETCHER CM, HUGHES GR: The normocomplementemic urticarial vasculitis syndrome-report of a case and response to colchicine. OM. Exp. Dermatol. (1991) 16(6):424–427.
   PubMed Web of Science ®Google Scholar
• SAIS G, VIDALLER A, JUCGLA A. GALLARDO F, PEYRI J: Colchicine in the treatment of cutaneous leucocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch. Dermatol. (1995) 131:1399–1402.
   Google Scholar
• CRIBIER B, CUNY JF, SCHBERT etal.: Recurrent annular erythema with purpura: a new variant of leucocytoclastic vasculitis responsive to dapsone. Br. I Dermatol. (1996) 135(6):972–975.
   Google Scholar
• EISER AR, SINGH P, SHANIES HM: Sustained dapsone-induced remission of hypocomplementemic urticarial vasculitis-a case report. Angiology (1997) 48(11):1019–1022.
   PubMed Web of Science ®Google Scholar
• GRAGGE J, HAAS N, MOLLER A, HENZ BM: Erythema elevatum diutinum-evidence for disease-dependent leucocyte alterations and response to dapsone. Br I Dermatol. (2000) 143(2):415–420.
   PubMed Web of Science ®Google Scholar
• MAILLARD H, SZCZESNIAK S, MARTIN L etal.: Cutaneous periarteritis nodosa: diagnostic and therapeutic aspects of 9 cases. {French} Armales de Dermatologie et de Vertereologie. (1999) 126(2):125–129.
   Google Scholar
• LIOZON F, VIDAL E, BARRIER J: Does Dapsone have a role in the treatment of temporal arteritis with regard to efficacy and toxicity? OM. Exp. Rheumatol. (1993) 11:694–695.
   PubMed Web of Science ®Google Scholar
• DOURY P, PATTIN S, DULRY F, THABOUT A: The use of dapsone in the treatment of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. (1983) 30:689–690.
   Google Scholar
• SPIERA H, SWERDLOW F: Dapsone as asteroid sparing agent in giant cell arteritis (GCA). Arthritis Rheum. (1987) 30\(Supp9:S62
   Google Scholar
• DEREMEE RA, MCDONALD TJ, WETLAND LH: Wegener's granulomatosis: observation and treatment with antimicrobial agents. Mayo Chit. Proc. (1985) 60:27–32.
   PubMed Web of Science ®Google Scholar
• STEGEMAN CA, COHEN TERVAERT JW, DE JONG PE, KALLENBERG CG DUTCH CO-TRIMOXAZOLE WEGENER STUDY GROUP:: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl. Med. (1996) 335:16–20.
   PubMed Web of Science ®Google Scholar
• REINHOLD-KELLER E, DEGROOT K etal.: Response to trimethoprim-sulfamethoxazole in Wegener's granulomatosis depends on the phases of the disease. WM (1996) 9(1):15–23.
   Google Scholar
• DEGROOT K, REINHOLD- KELLER E, GROSS WL et al.: Therapy for the maintenance of remission in sixty-five patients with generalized wegener's granulomatosis. methotrexate versus trimethoprim-sulfamethoxazole. Arthritis Rheum. 39(12):2052–2061.
   Google Scholar
• TREPO C, OUZAN D, DELMONT J, TREMISI J: Superiority of a new etiopathogenic treatment curing periarteritis nodosa caused by hepatitis B virus, using a combination of brief corticotherapy, vidarabine and plasma exchange. [French] Presse Medicale (1988) 17(30):1527–1531.
   PubMedGoogle Scholar
• GUILLEVIN L, LHOTE F, COHEN P et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (1995) 74(5):238–253.
   Google Scholar
• WICKI J, OLIVIERI J, PIZZOLATO G et al.: Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha. Rheumatology (Oxford). (1999) 38(2):183–185.
   PubMed Web of Science ®Google Scholar
• MACLACHLAN D, BATTEGAY M, JACOB AL, TYNDALL A: Successful treatment of hepatitis B-associated polyarteritis nodosa with a combination of lamivudine and conventional immunosuppressive therapy: a case report [letter]. Rheumatology (Oxford) (2000) 39:106–108.
   PubMed Web of Science ®Google Scholar
• MALNICK SD, BEERGABEL M, LURIE Y: Treatment of chronic hepatitis C virus infection. Ann. Pharmacother (US) (2000) 34(10):1156–1164.
   PubMed Web of Science ®Google Scholar
• SCHLANSKY, R, DEHORATIUS RJ, PINCUS T, TUNG KS: Plasmapheresis in systemic lupus erythematosus: A cautionary note. Arthritis Rheum. (1981) (4):280–286
   Google Scholar
• PUSEY CD, REES AJ, EVANS DJ et al.: Plasma exchange in focal necrotising glomerrulonephritis without anti GBM antibodies. Kidney Int. (1991) 40:757–763
   PubMed Web of Science ®Google Scholar
• GUILLEVIN L, JARROUSE B, LOK C et al.: Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. j Rheumatol. (1991) 18(4):567–574.
   Google Scholar
• SINICO RA, FORNASIERI A, FIORINI G etal.: Plasma exchange in the treatment of essential mixed cryoglobulinemia nephropathy. Long term follow up. Int. Artil Organs (1985) 8\(Suppl. 2):15.
   Google Scholar
• TAYLOR HG, SAMANTA A: Treatment of vasculitis. Br j Chit. Pharmacol. (1993) 35(2):93–104
   PubMed Web of Science ®Google Scholar
• STEGMAYR BG, ALMROTH G, BERLIN G et al.: Plasma exchange or immunoadsorption in patients with rapidly progressive glomerulonephritis. A Swedish multicenter study. Int. I Artil Organs (1999) 22:81–87.
   PubMed Web of Science ®Google Scholar
• ELLIOT JD, LOCKWOOD CM, HALE G, WALDMANN H: Semi-specific immuno-absorption and monoclonal antibody therapy in ANCA positive vasculitis: experiences in four cases. AutoimmuniO, (1998) 28:163–171
   PubMed Web of Science ®Google Scholar
• SHORT AK, LOCKWOOD CM, BOLLEN A, MOGUILESVSKY N: Neutrophil and recombinant myeloperoxidase as antigens in ANCA positive systemic vasculitis. Chit. Exp. Lumina (1995) 102:106–111.
   PubMed Web of Science ®Google Scholar
• YANAGAWA H, NAKAMURA Y, SAKATA K et al.: Use of intravenous gamma globulin for Kawasaki disease; effects on cardiac sequelae. Pediatr Cardiol. (1997) 18:19.
   PubMed Web of Science ®Google Scholar
• JAYNE DR, LOCKWOOD CM: Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br I Rheumatol. (1996) 35:1150–1153.
   PubMedGoogle Scholar
• BOOM BW, BRAND A, VERMEER BJ et al.: Severe leucocytoclastic vasculitis of the skin in a patient with essential mixed cryoglobulinemia treated with high-dose gamma-globulin intravenously. Arch. Dermatol. (1988) 124(10):1550–1553.
   PubMed Web of Science ®Google Scholar
• MISIANI R, BELLAVITA P, FENILI D et al.: Interferon alpha-2a therapy in cryoglobinemia asoociated with hepatitis C virus. N Engl. J. Med. (1994) 330:751–756.
   PubMed Web of Science ®Google Scholar
• BONOMO L, CASATO M, AFELTRA A, CACCAVO D: Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am. j Med. (1987) 83:726–730.
   PubMed Web of Science ®Google Scholar
• KOTTER I, ECKSTEIN AK, STUBIGER N, ZIERHUT M: Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a; a pilot study. Br Ophthal. (1998) 82(5):488–494.
   PubMed Web of Science ®Google Scholar
• MAINI RN, TAYLOR PC: Anti-cytokine therapy for rheumatoid arthritis. Ann Rev Med. (2000):207–229.
   PubMed Web of Science ®Google Scholar
• ENBREL PACKAGE INSERT: Revised 2000 by the Immuriex Corporation.
   Google Scholar
• NORONHA IL, KRUGER C, ANDRASSY K, RITZ E, WALDHERR R: In situ production of TNF-a, IL-113 and IL-2R in ANCA -positive glomerulonephritis. Kidney lid (1993) 43:682–692.
   PubMed Web of Science ®Google Scholar
• DEGUCHI Y, SHIBATA N, KISHIMOTO S: Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Cliri. Exp. ImmurioL (1990) 81:311–314.
   PubMed Web of Science ®Google Scholar
• STONE J, UHLFELDER M, HELLMANN D, CROOKS S, BEDOCS N, HOFFMAN G: Etanercept combined with conventional treatment in Wegener's Granulomatosis: a six-month open-label trial to evaluate safety. In 2000 ASMafAm. Coll. Rheumatol Arthritis Rheum. (2001) 44(5):1149–1154 (Abstract 2024).
   Google Scholar
• KAM LY, TARGAN SR: TNF-a antagonists for the treatment of Crohn's disease. Expert Opiri. Pharmacother. (2000) 1(5):1041–1052.
   PubMedGoogle Scholar
• LOCKWOOD CM: Refractory Wegener's granolomatosis: a model for shorter immunotherapy of autoimmune diseases. R. Coll. Physicians London. (1998) 32(5):473–478.
   PubMed Web of Science ®Google Scholar
• HAGEN EC, DE KEIZER RJW, ANDRASSY K et al.: Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Cliri. Nephrol. (1995) 6:351–359.
   Google Scholar
• SLAVIN S: Treatment of life-threatening autoimmune disease with myeloablative doses of immunosuppressive agents:experimental background and rationale for ABMT. Bone Marrow Transplaritat. (1993) 12(1):85–88.
   PubMed Web of Science ®Google Scholar
• NELSON JL, TORREZ R, SULLIVAN KM et al. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. .1. Rheumatol. (1997) 48(Suppl.):23–29.
   Google Scholar
• COHEN TERVAERT JW, STEGEMAN CA, KALLENBERG CG: Novel therapies for anti-neutrophilcytoplasmic antibody-associated vasculitis. (2001) 10(30)211–217.
   Google Scholar
• GROSS WL: New concepts in treatment protocols for severe systemic vasculitis. Curr. Opiri. RheumatoL (1999) 11(1):41–46.
   PubMedGoogle Scholar
• TOLEDO DE, CODINA JS, GALINDO CR etal.: Response of central nervous system vasculitis to irradiation. Lancet (1991) 337:1105–1106.
   Google Scholar